Base de dados : MEDLINE
Pesquisa : K01.752.566.479.095 [Categoria DeCS]
Referências encontradas : 8912 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 892 ir para página                         

  1 / 8912 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29362787
[Au] Autor:Grundy Q; Dunn AG; Bourgeois FT; Coiera E; Bero L
[Ad] Endereço:Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
[Ti] Título:Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores.
[So] Source:JAMA;319(4):408-409, 2018 01 23.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Bibliometria
Conflito de Interesses
Revelação/estatística & dados numéricos
Políticas Editoriais
Publicações Periódicas como Assunto/normas
[Mh] Termos MeSH secundário: Estudos Transversais
Fator de Impacto de Revistas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180311
[Lr] Data última revisão:
180311
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.20738


  2 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29292914
[Au] Autor:Eberhard J
[Ti] Título:Grova anklagelser mot skånsk onkologi kan inte stå oemotsagda..
[So] Source:Lakartidningen;114, 2017 11 02.
[Is] ISSN:1652-7518
[Cp] País de publicação:Sweden
[La] Idioma:swe
[Mh] Termos MeSH primário: Neoplasias Colorretais/tratamento farmacológico
Fidelidade a Diretrizes
[Mh] Termos MeSH secundário: Conflito de Interesses
Indústria Farmacêutica
Hospitais Universitários/normas
Seres Humanos
Suécia
[Pt] Tipo de publicação:LETTER
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE


  3 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29222543
[Au] Autor:Ioannidis JPA; Trepanowski JF
[Ad] Endereço:Stanford Prevention Research Center, Department of Medicine and Departments of Health Research and Policy, Biomedical Data Science, and Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California.
[Ti] Título:Disclosures in Nutrition Research: Why It Is Different.
[So] Source:JAMA;319(6):547-548, 2018 02 13.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Pesquisa Biomédica/ética
Conflito de Interesses
Revelação/ética
Ciências da Nutrição/ética
[Mh] Termos MeSH secundário: Dieta
Indústria Alimentícia/ética
Seres Humanos
Ciências da Nutrição/economia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171210
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.18571


  4 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181951
[Au] Autor:Lie AL; Granheim SI
[Ti] Título:Multistakeholder partnerships in global nutrition governance: protecting public interest?.
[So] Source:Tidsskr Nor Laegeforen;137(22), 2017 11 28.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:nor
[Mh] Termos MeSH primário: Saúde Global
Cooperação Internacional
Política Nutricional
[Mh] Termos MeSH secundário: Conflito de Interesses
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.17.0627


  5 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464141
[Au] Autor:Larkin I; Ang D; Steinhart J; Chao M; Patterson M; Sah S; Wu T; Schoenbaum M; Hutchins D; Brennan T; Loewenstein G
[Ad] Endereço:University of California, Los Angeles.
[Ti] Título:Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing.
[So] Source:JAMA;317(17):1785-1795, 2017 May 02.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing. Objective: To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs. Design, Setting, and Participants: The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy. Exposures: Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians. Main Outcomes and Measures: The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability. Results: The analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage points; P < .001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P < .001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas. Conclusions and Relevance: Implementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies.
[Mh] Termos MeSH primário: Centros Médicos Acadêmicos/estatística & dados numéricos
Conflito de Interesses
Indústria Farmacêutica
Prescrições de Medicamentos/estatística & dados numéricos
Política Organizacional
Médicos/estatística & dados numéricos
Medicamentos sob Prescrição/uso terapêutico
[Mh] Termos MeSH secundário: Anticolesterolemiantes/uso terapêutico
Antidepressivos/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Antipsicóticos/uso terapêutico
California
Fármacos Cardiovasculares/uso terapêutico
Seres Humanos
Hipnóticos e Sedativos/uso terapêutico
Hipoglicemiantes/uso terapêutico
Illinois
Relações Interprofissionais
Massachusetts
New York
Pennsylvania
Análise de Regressão
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Antidepressive Agents); 0 (Antihypertensive Agents); 0 (Antipsychotic Agents); 0 (Cardiovascular Agents); 0 (Hypnotics and Sedatives); 0 (Hypoglycemic Agents); 0 (Prescription Drugs)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.4039


  6 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29359904
[Au] Autor:Lee A; Berry MD; Thomson Reuters Accelus.
[Ti] Título:Healthcare Workforce.
[So] Source:Issue Brief Health Policy Track Serv;2017:[1-59], 2017 Dec 26.
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Recursos Humanos em Saúde/legislação & jurisprudência
Recursos Humanos em Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Conflito de Interesses
Consciência
Odontólogos/provisão & distribuição
Educação em Enfermagem
Serviços de Assistência Domiciliar/recursos humanos
Seres Humanos
Licenciamento
Profissionais de Enfermagem
Enfermagem/recursos humanos
Admissão e Escalonamento de Pessoal
Assistentes Médicos
Médicos/provisão & distribuição
Atenção Primária à Saúde/recursos humanos
Salários e Benefícios
Governo Estadual
Telemedicina
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  7 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241283
[Au] Autor:Lieb K; Koch C
[Ti] Título:[There is no Season for Gifts].
[Ti] Título:Auch zu Weihnachten keine Geschenke!.
[So] Source:Dtsch Med Wochenschr;142(25):1949-1953, 2017 Dec.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Gifts and payments from pharmaceutical manufacturers to medical doctors constitute a conflict of interest, which may lead to an undue influence on prescribing behavior. In Germany, 35 research-based pharmaceutical companies, organized in the "Verband der forschenden Arzneimittelhersteller (VfA)" paid €â€Š562 million to medical doctors and hospitals in 2016. Of these, €â€Š356 million were paid for clinical trials and non-interventional studies, €â€Š105 million for sponsored presentations and CME and €â€Š101 million went to hospitals and other organizations for sponsoring, consulting and events. This article gives a short review on the different kinds of interactions, discusses psychological mechanisms and legal aspects of accepting gifts and recommends not to accept any gifts and donations from pharmaceutical companies to avoid undue influences on prescribing behavior. There are many ways to keep up to date using independent sources of information, and independent CME-events are growing in number - examples are given.
[Mh] Termos MeSH primário: Conflito de Interesses/legislação & jurisprudência
Indústria Farmacêutica
Doações/ética
Relações Interprofissionais/ética
Médicos
[Mh] Termos MeSH secundário: Indústria Farmacêutica/economia
Indústria Farmacêutica/ética
Seres Humanos
Médicos/economia
Médicos/ética
Médicos/legislação & jurisprudência
Padrões de Prática Médica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-120838


  8 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28749536
[Au] Autor:Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
[Ad] Endereço:Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
[Ti] Título:The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
[So] Source:Cancer;123(22):4356-4362, 2017 Nov 15.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Interactions between industry and prescribers have raised concerns regarding conflicts of interest. To the best of the authors' knowledge, quantitative data measuring these interactions have been limited until recently. In the current study, the authors sought to determine whether an association exists between industry payments and prescriber behavior with regard to abiraterone and enzalutamide. METHODS: Two Centers for Medicare and Medicaid Services databases were combined to analyze oncologists and urologists who received industry payments and/or prescribed abiraterone and enzalutamide. Correlation analysis was constructed on prescription count and industry payments. Multivariable median regression examined predictors of change in prescription count per dollar of industry payment. Stratifying prescribers by quantile evaluated threshold effects on prescribers. RESULTS: The number of prescriptions was similar between prescribers who did and those who did not receive industry payment for both drugs. The median industry payment amount to prescribers differed between prescribers and nonprescribers for abiraterone ($72 vs $56) and enzalutamide ($59 vs $31). Although no statistical association was found to exist between industry payment amount and prescription count for abiraterone prescribers, an association was found to exist for enzalutamide prescribers (rho = 0.31). A small change was found with regard to prescription count per dollar of industry payment for abiraterone (0.0007 prescriptions) and enzalutamide (0.0006 prescriptions). The amount of industry payment needed to predict one additional prescription was found to be lower in the fourth and fifth quantiles compared with the first through third quantiles. CONCLUSIONS: No difference in prescription count was found to exist between prescribers who received industry payments and those who did not. A positive correlation was noted between industry payments and prescription count for enzalutamide. Ease of adoption may affect differences between the 2 drugs. Cancer 2017;123:4356-62. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Androstenos/economia
Androstenos/uso terapêutico
Indústria Farmacêutica/economia
Medicare/economia
Feniltioidantoína/análogos & derivados
Padrões de Prática Médica/economia
[Mh] Termos MeSH secundário: Conflito de Interesses
Custos de Medicamentos
Indústria Farmacêutica/ética
Ética Médica
Gastos em Saúde/estatística & dados numéricos
Seres Humanos
Revisão da Utilização de Seguros
Medicare/estatística & dados numéricos
Feniltioidantoína/economia
Feniltioidantoína/uso terapêutico
Médicos/economia
Médicos/ética
Padrões de Prática Médica/ética
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstenes); 0 (MDV 3100); 2010-15-3 (Phenylthiohydantoin); G819A456D0 (abiraterone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30914


  9 / 8912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29074628
[Au] Autor:Liu JJ; Bell CM; Matelski JJ; Detsky AS; Cram P
[Ad] Endereço:Department of Medicine, University of Toronto, Toronto, Ontario, Canada jessica.liu@uhn.ca.
[Ti] Título:Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study.
[So] Source:BMJ;359:j4619, 2017 Oct 26.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo: To estimate financial payments from industry to US journal editors. Retrospective observational study. 52 influential (high impact factor for their specialty) US medical journals from 26 specialties and US Open Payments database, 2014. 713 editors at the associate level and above identified from each journal's online masthead. All general payments (eg, personal income) and research related payments from pharmaceutical and medical device manufacturers to eligible physicians in 2014. Percentages of editors receiving payments and the magnitude of such payments were compared across journals and by specialty. Journal websites were also reviewed to determine if conflict of interest policies for editors were readily accessible. Of 713 eligible editors, 361 (50.6%) received some (>$0) general payments in 2014, and 139 (19.5%) received research payments. The median general payment was $11 (£8; €9) (interquartile range $0-2923) and the median research payment was $0 ($0-0). The mean general payment was $28 136 (SD $415 045), and the mean research payment was $37 963 (SD $175 239). The highest median general payments were received by journal editors from endocrinology ($7207, $0-85 816), cardiology ($2664, $0-12 912), gastroenterology ($696, $0-20 002), rheumatology ($515, $0-14 280), and urology ($480, $90-669). For high impact general medicine journals, median payments were $0 ($0-14). A review of the 52 journal websites revealed that editor conflict of interest policies were readily accessible (ie, within five minutes) for 17/52 (32.7%) of journals. Industry payments to journal editors are common and often large, particularly for certain subspecialties. Journals should consider the potential impact of such payments on public trust in published research.
[Mh] Termos MeSH primário: Conflito de Interesses
Indústria Farmacêutica/economia
Políticas Editoriais
Equipamentos e Provisões
Indústria Manufatureira/economia
Publicações Periódicas como Assunto/economia
Publicações Periódicas como Assunto/ética
[Mh] Termos MeSH secundário: Pesquisa Biomédica/economia
Seres Humanos
Renda
Estudos Retrospectivos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171028
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j4619


  10 / 8912 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28985847
[Au] Autor:Cherla DV; Olavarria OA; Holihan JL; Viso CP; Hannon C; Kao LS; Ko TC; Liang MK
[Ad] Endereço:Department of Surgery, Lyndon Baines Johnson Hospital, University of Texas, Houston, Texas. Electronic address: deepa.cherla@uth.tmc.edu.
[Ti] Título:Discordance of conflict of interest self-disclosure and the Centers of Medicare and Medicaid Services.
[So] Source:J Surg Res;218:18-22, 2017 Oct.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The Open Payments Database (OPD) discloses financial transactions between manufacturers and physicians. The concordance of OPD versus self-reported conflicts of interest (COI) is unknown. MATERIALS AND METHODS: Our objectives were to compare (1) industry and self-disclosed COI in clinical literature, (2) payments within each disclosure level, and (3) industry- and self-disclosed COI and payments by specialty. This was an observational study. PubMed was searched for clinical studies accepted for publication from January 2014 to June 2016. Author and OPD-disclosed COIs were compared. Articles and authors were divided into full disclosure, incomplete industry disclosure, incomplete self-disclosure, and no COI. Primary outcome (differences in reported COI per article) was assessed using McNemar's test. Payment differences were compared using Kruskal-Wallis test. RESULTS: OPD- and self-disclosed COI differed (65.0% discordance rate by article, P < 0.001). Percentages of authors within each disclosure category differed between specialties (P < 0.001). Hematology articles exhibited the highest discordance rate (79.0%) and received the highest median payment for incomplete self-disclosure ($30,812). CONCLUSIONS: Significant discordance exists between self- and OPD-reported COI. Additional research is needed to determine reasons for these differences.
[Mh] Termos MeSH primário: Centers for Medicare and Medicaid Services (U.S.)
Conflito de Interesses/economia
Bases de Dados Factuais
Revelação/estatística & dados numéricos
Apoio Financeiro
Médicos
Autorrelato/utilização
[Mh] Termos MeSH secundário: Conflito de Interesses/legislação & jurisprudência
Revelação/legislação & jurisprudência
Indústria Farmacêutica/economia
Indústria Farmacêutica/legislação & jurisprudência
Apoio Financeiro/ética
Seres Humanos
Médicos/economia
Médicos/ética
Médicos/legislação & jurisprudência
Médicos/estatística & dados numéricos
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171008
[St] Status:MEDLINE



página 1 de 892 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde